Lv2
148 积分 2022-07-21 加入
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations
6天前
已完结
Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre
11天前
已完结
Comparative predictive value of immunotherapy biomarkers: a systematic review and network meta-analysis
20天前
已完结
IL-6 drives chemoimmunotherapy resistance in NSCLC by reprogramming myeloid cells and impairing cytotoxic lymphocyte function
20天前
已完结
IL4I1⁺ Macrophages and TDO2⁺ Myofibroblasts Drive AhR‐Mediated Immunosuppression and Ferroptosis Resistance in Solid Predominant Lung Adenocarcinoma
20天前
已完结
Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study
1个月前
已完结
A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients receiving PD-1/PD-L1 inhibitors
1个月前
已完结
Distinct Tumor-Immune Ecologies in Lung Cancer PatientsPredict Progression and Define a Clinical Biomarker of Therapy Response
1个月前
已完结
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
1个月前
已完结
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial
1个月前
已完结
皖公网安备34019202002308
